13F filer · CIK 2026172
DIADEMA PARTNERS LP
MORRISTOWN, NJ · filing since Q4 2024 · last filing Aug 14, 2026
Reported value
$791.3M
+$203.6M vs prior
Positions
149
New / sold out
69 / 64
Added / reduced
35 / 24
Turnover
48.3%
buys $471.4M · sells $333.0M
Top-10 weight
37.3%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | BRISTOL-MYERS SQUIBB COCALL | +600,000 | – | +$34.6M |
| Added | ABIVAX SACALL | +249,200 | +249.2% | +$33.2M |
| Added | VIKING THERAPEUTICS INCCALL | +561,600 | +85.2% | +$21.9M |
| Added | ABIVAX SAPUT | +152,400 | +152.4% | +$20.3M |
| New | BRISTOL-MYERS SQUIBB COPUT | +330,600 | – | +$19.0M |
| New | BRIDGEBIO PHARMA INC | +250,000 | – | +$18.6M |
| New | KYMERA THERAPEUTICS INCCALL | +149,700 | – | +$17.2M |
| New | NOVARTIS AGPUT | +100,000 | – | +$15.7M |
| Added | UNITED THERAPEUTICS CORP DEL | +25,686 | +94.1% | +$13.9M |
| New | VIKING THERAPEUTICS INCPUT | +350,500 | – | +$13.7M |
94 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | VERTEX PHARMACEUTICALS INCCALL | -93,100 | -100.0% | $-41.6M |
| Sold out | LIQUIDIA CORPORATIONCALL | -662,100 | -100.0% | $-25.0M |
| Sold out | UNITED THERAPEUTICS CORP DELCALL | -40,200 | -100.0% | $-23.8M |
| Sold out | APOGEE THERAPEUTICS INCCALL | -222,500 | -100.0% | $-18.7M |
| Sold out | BRIDGEBIO PHARMA INC | -250,000 | -100.0% | $-18.6M |
| Reduced | CYTOKINETICS INCPUT | -170,000 | -85.0% | $-14.5M |
| Sold out | REVOLUTION MEDICINES INCPUT | -125,500 | -100.0% | $-12.2M |
| Sold out | MERCK & CO INCPUT | -100,000 | -100.0% | $-12.0M |
| Sold out | UNITED THERAPEUTICS CORP DELPUT | -20,000 | -100.0% | $-11.9M |
| Sold out | JAZZ PHARMACEUTICALS PLC | -54,755 | -100.0% | $-10.4M |
78 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | VIKING THERAPEUTICS INCCALLCOM | 1,220,800 | $47.6M | 6.02% |
| 2 | ABIVAX SACALLSPONSORED ADS | 349,200 | $46.5M | 5.88% |
| 3 | BRISTOL-MYERS SQUIBB COCALLCOM | 600,000 | $34.6M | 4.37% |
| 4 | ABIVAX SAPUTSPONSORED ADS | 252,400 | $33.6M | 4.25% |
| 5 | UNITED THERAPEUTICS CORP DELCOM | 52,989 | $28.7M | 3.63% |
| 6 | REVOLUTION MEDICINES INCCOM | 139,218 | $26.1M | 3.29% |
| 7 | ABIVAX SASPONSORED ADS | 163,644 | $21.6M | 2.73% |
| 8 | COGENT BIOSCIENCES INCCOM | 493,664 | $19.1M | 2.41% |
| 9 | BRISTOL-MYERS SQUIBB COPUTCOM | 330,600 | $19.0M | 2.41% |
| 10 | BRIDGEBIO PHARMA INCNOTE 1.750% 3/0 | 250,000 | $18.6M | 2.35% |
139 more rows. Subscribe for $29/month to see every row, download the data and use the API.